<DOC>
	<DOCNO>NCT01987986</DOCNO>
	<brief_summary>To assess safety effectiveness repeat dose AA4500 treatment edematous fibrosclerotic panniculopathy ( EFP ) commonly know cellulite adult woman .</brief_summary>
	<brief_title>A Phase 2 , Randomized , Double-blind , Placebo Controlled Dose Ranging Study Repeat Doses AA4500 Treatment Edematous Fibrosclerotic Panniculopathy</brief_title>
	<detailed_description>The Phase 2a study randomize , double-blind multiple-dose study expect enroll approximately 144 woman age 18 45 United States . Treatment effectiveness evaluate investigator patient assessment , well 3-D photographic image technique . Once safety local tolerability profile first stage find acceptable subject enrol stage 2 . After interim safety local tolerability review complete subject stage 1 , determine enrollment stage 2 acceptable initiate .</detailed_description>
	<mesh_term>Edema</mesh_term>
	<criteria>1 . Be female 18 45 year age . 2 . Have least one well defined dimple least 1 cm 2 cm along long axis evident subject stand 3 . Have photonumeric cellulite severity scale ( CSS ) score 6 12 4 . Have Body Mass Index ( BMI ) &gt; 19 &lt; 30 kg/m2 , intend maintain stable body weight throughout duration study 5 . Be willing apply appropriate sunscreen select quadrant exposure sun participate study 6 . Be judge good health , base upon result medical history , physical examination , laboratory profile screen . 7 . Have negative urine pregnancy test screen injection AA4500 use effective contraception method ( ie , abstinence , intrauterine device [ IUD ] , hormonal [ estrogen/progestin ] contraceptive , barrier control ) least one menstrual cycle prior study enrollment duration study . 8 . Be willing able cooperate requirement study . 9 . Voluntarily sign date inform consent agreement approve Institutional Review Board/Independent Ethics Committee/Human Research Ethics Committee ( IRB/IEC/HREC ) . 10 . Be able read , complete understand Patient Reported Outcomes rating instrument English . 1 . Thyroid disease , unless control medication ≥ 6 month 2 . Uncontrolled diabetes mellitus , determine investigator 3 . Uncontrolled hypertension , determine investigator 4 . Vascular disorder ( eg , phlebitis varicose vein ) area treat 5 . Lipedema lymphatic disorder 6 . Cushing 's disease and/or use systemic corticosteroid 7 . History low extremity thrombosis postthrombosis syndrome 8 . Documented autoimmune disorder lupus erythematosus , rheumatoid arthritis 9 . Inflammation active infection area treat 10 . Cutaneous alteration area treat 11 . Rash , eczema , psoriasis , skin cancer area treat 12 . History keloidal scar abnormal wound heal 13 . Coagulation disorder 14 . Taking medication chronic anticoagulation ( except ≤ 150 mg aspirin daily ) 15 . Known active hepatitis A , B C 16 . Known immune deficiency disease positive test human immunodeficiency virus ( HIV ) 17 . Other significant condition include body dysmorphic disorder , investigator 's opinion would make subject unsuitable enrollment study 18 . Is menopausal defined 12 month amenorrhea absence biological physiological cause , determine investigator 19 . Has use follow treatment EFP legs buttock within timeline identify intend use following time course study : Liposuction side body select treatment 12month period injection AA4500 Injections ( eg , mesotherapy ) ; radiofrequency device treatment ; laser treatment ; surgery ( include subcision ) within select treatment quadrant 12month period injection AA4500 Endermologie similar treatment within select treatment quadrant 6months period injection AA4500 Massage therapy within select treatment quadrant 3month period injection AA4500 Creams ( eg , Celluvera™ , TriLastin® ) prevent mitigate EFP within select treatment quadrant 2week period injection AA4500 20 . Has tattoo locate within 2 cm site injection 21 . Is presently nursing baby provide breast milk baby . 22 . Intends become pregnant study . 23 . Intends initiate intensive sport exercise program study . 24 . Has receive investigational drug treatment within 30 day injection AA4500 . 25 . Has know systemic allergy collagenase excipient AA4500 . 26 . Has receive collagenase treatment within 30 day treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>cellulite</keyword>
	<keyword>dimple</keyword>
	<keyword>orange peel</keyword>
	<keyword>cottage cheese</keyword>
	<keyword>mattress texture</keyword>
</DOC>